# Genmab: Phase 2 study closed enrollment, 666 enrolled (DLBCL, High-grade B-cell Lymphoma (HGBCL))

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Genmab |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma |
| NCT ID | NCT03625037 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | DLBCL; High-grade B-cell Lymphoma (HGBCL); Primary Mediastinal Large B-cell Lymphoma (PMBCL); FL; MCL; Small Lymphocytic Lymphoma (SLL) |
| Intervention types | biological |
| Target enrollment | 666 |
| Site countries | United States, Australia, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Singapore, South Korea |
| Posted | 2018-08-10 |
| Planned start | 2018-06-26 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 666 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03625037). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.